Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- The company disclosed that WBA accounted for approximately 26% of revenue in 2024, down from 28%. This change might result in a significant revenue impact.
- The Distributor Settlement Agreement includes a cash component of $418.0 million over 18 years, impacting financial position.
- In October 2024, WBA announced plans to close approximately 1,200 retail stores over three years, potentially adversely affecting our business and financial position.
- Ongoing lawsuits related to opioid and other controlled substances could adversely affect financial position and operations.
- The company acquired PharmaLex for $1.473 billion in cash and invested $718.4 million in OneOncology, which may disrupt existing relationships and operations.
- New cybersecurity risks from third-party partners could significantly disrupt operations and impact business continuity.
- The accrued litigation liability related to the Distributor Settlement Agreement is now $4.9 billion, with $630 million expected to be paid before September 30, 2025.
- Increased focus on ESG initiatives may influence reputation and could have a material adverse effect on results of operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1140859&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.